TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00768638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
Study: NCT03461679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block
Description: Single shot block with 0.5% bupivacaine 10mls

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral triangle block
Description: Single shot block with 0.5% bupivacaine 10mls

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral triangle block
Description: Single shot block with 0.5% bupivacaine 10mls
Study: NCT02692261

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Augmentation
Description: Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Augmentation
Description: Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Augmentation
Description: Control group sinuses filled with heterolog bone graft alone
Study: NCT04626310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy - emotion regulation skills training
Description: Arm 1. Dialectical behavior therapy - emotion regulation skills training follows the emotion regulation skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.~Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy - interpersonal effectiveness skills training
Description: Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal psychotherapy
Description: Arm 3. Non-skills-oriented interpersonal psychotherapy group follows evidence-based principles on common factors in a group therapy context. This group involves 6 weekly sessions.
Study: NCT02397564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser, traditional and fractional settings
Description: Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
Study: NCT02692261

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Augmentation
Description: Control group sinuses filled with heterolog bone graft alone
Study: NCT01963663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30 mg daily in two divided doses of 15 mg tablets
Study: NCT01756807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The COMBO Stent
Description: The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
Study: NCT03277963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)
Description: From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)
Description: From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
Study: NCT02539628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0.2%
Description: Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Description: Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
Study: NCT02901028

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laboratory testing
Description: Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory testing
Description: Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
Study: NCT03309475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SocialMIND
Description: SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational multicomponent intervention
Description: The psychoeducational multicomponent intervention addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Treatment as usual delivered by patient's practitioner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment
Description: Treatment as usual delivered by patient's practitioner
Study: NCT02901028

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood and Urine Draws
Description: subjects will have a blood draw and provide a urine sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Urine Draws
Description: subjects will have a blood draw and provide a urine sample
Study: NCT02993562

Intervention type: DRUG
Intervention: Levothyroxine
Description: Normal treatment with levothyroxine.
Study: NCT00833534

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study: NCT01246687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Intervention
Description: Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
Study: NCT03216967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
Study: NCT04578080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
Study: NCT03216967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
Study: NCT04210557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.
Study: NCT03030664

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L.reuteri
Description: Each day, at about the same time, the subjects will be given 5 drops (1x10\^8 CFU) of the study product in connection with feeding

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same formulation as study product, without probiotics.
Study: NCT02475213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
Study: NCT03309475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychotropic treatment
Description: Treatment as usual delivered by patient's practitioner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotropic treatment
Description: Treatment as usual delivered by patient's practitioner
Study: NCT02681432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No HIPEC
Description: Cytoreductive surgery without HIPEC
Study: NCT00850187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow derived mesenchymal stem cells
Description: Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
Study: NCT02475213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
Study: NCT04578080

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
Study: NCT03920020

Intervention type: OTHER
Group type: OTHER
Intervention: the concentric isokinetic exercise group
Description: concentric isokinetic exercises

Intervention type: OTHER
Group type: OTHER
Intervention: the eccentric isokinetic exercise group
Description: eccentric isokinetic exercises

Intervention type: OTHER
Group type: OTHER
Intervention: the control group
Description: conventional physiotherapy and standard therapeutic exercises predetermined by us

Intervention type: OTHER
Group type: OTHER
Intervention: the control group
Description: conventional physiotherapy and standard therapeutic exercises predetermined by us

Intervention type: OTHER
Group type: OTHER
Intervention: the control group
Description: conventional physiotherapy and standard therapeutic exercises predetermined by us
Study: NCT01367756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4995819
Description: multiple oral doses, Days 10-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: multiple oral doses, Days 1-16

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: citalopram
Description: multiple oral doses, Days 1-16

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple oral doses, Days 10-16
Study: NCT05960123

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubularized Incised Plate (TIP) urethroplasty
Description: tubularization of urethral plate with or without spongioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubularized Incised Plate (TIP) urethroplasty
Description: tubularization of urethral plate with or without spongioplasty
Study: NCT00414609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren was available in 75 mg tablet, 150 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
Study: NCT01819480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Description: Transoral robotic surgery using the daVinci robot to remove primary tumor
Study: NCT01169909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
Study: NCT02884960

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Fibroid Embolization
Description: This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Fibroid Embolization
Description: This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
Study: NCT02256800

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (6,6)
Description: The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGTIA1 genotyping (6,7)
Description: The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2.
Study: NCT02195687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
Study: NCT00479583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-690514 / FOLFIRI
Description: Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-690514 / FOLFOX
Description: Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
Study: NCT02905435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable Temporizing Matrix
Description: The Biodegradable Temporizing Matrix (BTM) (also known as NovoSorb BTM) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
Study: NCT02475213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGA012
Description: anti-PD-1 monoclonal antibody
Study: NCT02502305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: liveonline course
Description: physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
Study: NCT03685708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV-B
Description: HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
Study: NCT01704105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water Quality
Description: Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water Quality
Description: Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water Quality
Description: Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanitation
Description: Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanitation
Description: Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanitation
Description: Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.